| Identification | Back Directory | [Name]
PXS-5153A | [CAS]
2125956-82-1 | [Synonyms]
PXS-5153A
(Z)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-N,N-dimethylbenzenesulfonamide Dihydrochloride | [Molecular Formula]
C20H24ClFN4O2S | [MDL Number]
MFCD31807634 | [MOL File]
2125956-82-1.mol | [Molecular Weight]
438.95 |
| Hazard Information | Back Directory | [Uses]
A useful intermediate in the preparation of haloallylamine indole and azaindole derivatives which are lysyl oxidases inhibitors. | [in vivo]
As expected, rhLOXL2 dose-dependently induce oxidation of collagen with PXS-5153A dose-dependently impeding collagen oxidation. Therapeutic treatment of PXS-5153A substantially reduces immature crosslink formation compared with the CCl4 treated animals. Mature crosslink formation is also reduced by PXS-5153A treatment. All groups with therapeutic treatment of PXS-5153A show a significant reduction in DHLNL formation compared to the CCl4 treated animals. Treatment with PXS-5153A causes a significantly reduction in HYP compared to the CCl4 group. In addition, the amount of fibrillar collagen is markedly augmented by disease as seen by the 2.2-fold increase in percentage coverage area by Picrosirius red staining, which is reduced by PXS-5153A[1]. |
|
| Company Name: |
hangzhoubaiyibiolog
|
| Tel: |
15658107580 |
| Website: |
www.chemicalbook.com/showsupplierproductslist1389215/0.htm |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|